The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| SHC | +4.73% | N/A | N/A | -34% |
| S&P | +19.61% | +98.99% | +14.75% | +93% |
Sotera Health Co. provides mission-critical sterilization, lab testing and advisory services to the medical device and pharmaceutical industries. It also provides end-to-end sterilization as well as microbiological and analytical lab testing and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients and consumers. The firm operates through the following businesses: Sterigenics, Nordion, and Nelson Labs. The Sterigenics business provides outsourced terminal sterilization and irradiation services for the medical device, pharmaceutical, food safety and advanced applications markets by using following technologies: gamma irradiation, EO processing and E-beam irradiation. The Nordion business provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process. The Nelson Labs business provides outsourced microbiological and analytical chemistry testing and advisory services for the medical device and pharmaceutical industries. The company was founded in 1978 and is headquartered in Broadview Heights, OH.
The company announced it had reached an agreement in a class action lawsuit.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $294.34M | 6.4% |
| Gross Profit | $157.32M | 14.5% |
| Gross Margin | 53.45% | 3.8% |
| Market Cap | $3.16B | -6.1% |
| Market Cap / Employee | $1.05M | 0.0% |
| Employees | 3K | 0.0% |
| Net Income | $7.96M | -9.0% |
| EBITDA | $140.48M | 11.8% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $334.27M | 34.9% |
| Accounts Receivable | $165.13M | 13.7% |
| Inventory | 65 | 5.2% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $2.33B | -0.1% |
| Short Term Debt | $23.66M | 26.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 0.77% | -0.5% |
| Return On Invested Capital | -0.82% | 0.5% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $23.87M | 350.2% |
| Operating Free Cash Flow | $55.10M | 70.2% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 67.28 | 87.97 | 134.64 | 132.86 | 56.81% |
| Price to Book | 10.06 | 8.24 | 8.16 | 7.62 | -2.59% |
| Price to Sales | 4.26 | 3.55 | 2.99 | 2.83 | -8.12% |
| Price to Tangible Book Value | -4.80 | -3.93 | -3.33 | -3.25 | 2.97% |
| Price to Free Cash Flow TTM | 66.71 | 86.71 | 30.85 | 22.60 | -99.24% |
| Enterprise Value to EBITDA | 50.77 | 42.23 | 47.40 | 36.97 | -15.17% |
| Free Cash Flow Yield | 1.5% | 1.2% | 3.2% | 4.4% | 13041.82% |
| Return on Equity | 16.6% | 10.5% | 5.9% | 5.1% | -45.76% |
| Total Debt | $2.36B | $2.35B | $2.35B | $2.35B | 0.11% |
SHC earnings call for the period ending December 31, 2024.
SHC earnings call for the period ending September 30, 2024.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
